Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gesche Tallen

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Oncology Research|January 14, 2010
The inhibitor of growth 1 (ING1) proteins suppress angiogenesis and differentially regulate angiopoietin expression in glioblastoma cellsGesche Tallen, Sonja Farhangi, Mona Tamannai, et al.
Plos One|July 7, 2011
The p53 tumor suppressor is stabilized by inhibitor of growth 1 (ING1) by blocking polyubiquitinationSubhash Thalappilly, Xiaolan Feng, Svitlana Pastyryeva, et al.
Personalized Medicine|May 11, 2021
Deliberations about clinical pharmacogenetic testing in pediatric oncologyAmalia M Issa, Sarah Ae Aboushawareb, David D Eisenstat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2010
Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90Gesche Tallen, Richard Ratei, Georg Mann, et al.
Journal of Neuro-Oncology|September 4, 2007
Down-regulation of the inhibitor of growth 1 (ING1) tumor suppressor sensitizes p53-deficient glioblastoma cells to cisplatin-induced cell deathUte Gesche Tallen, Matthias Truss, Frank Kunitz, et al.
Leukemia & Lymphoma|August 2, 2018
Clinical significance of cytogenetic changes in childhood T-cell acute lymphoblastic leukemia: results of the multicenter group Moscow-Berlin (MB)Yulia Olshanskaya, Anna Kazakova, Grigory Tsaur, et al.
Journal of Cancer Research and Clinical Oncology|March 7, 2019
Reduced vs. standard dose native E. coli-asparaginase therapy in childhood acute lymphoblastic leukemia: long-term results of the randomized trial Moscow-Berlin 2002Alexander Karachunskiy, Gesche Tallen, Julia Roumiantseva, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|August 18, 2015
Strategies to improve the quality of survival for childhood brain tumour survivorsGesche Tallen, Anika Resch, Gabriele Calaminus, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Oncology Research|January 14, 2010
The inhibitor of growth 1 (ING1) proteins suppress angiogenesis and differentially regulate angiopoietin expression in glioblastoma cellsGesche Tallen, Sonja Farhangi, Mona Tamannai, et al.
Plos One|July 7, 2011
The p53 tumor suppressor is stabilized by inhibitor of growth 1 (ING1) by blocking polyubiquitinationSubhash Thalappilly, Xiaolan Feng, Svitlana Pastyryeva, et al.
Personalized Medicine|May 11, 2021
Deliberations about clinical pharmacogenetic testing in pediatric oncologyAmalia M Issa, Sarah Ae Aboushawareb, David D Eisenstat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2010
Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90Gesche Tallen, Richard Ratei, Georg Mann, et al.
Journal of Neuro-Oncology|September 4, 2007
Down-regulation of the inhibitor of growth 1 (ING1) tumor suppressor sensitizes p53-deficient glioblastoma cells to cisplatin-induced cell deathUte Gesche Tallen, Matthias Truss, Frank Kunitz, et al.
Leukemia & Lymphoma|August 2, 2018
Clinical significance of cytogenetic changes in childhood T-cell acute lymphoblastic leukemia: results of the multicenter group Moscow-Berlin (MB)Yulia Olshanskaya, Anna Kazakova, Grigory Tsaur, et al.
Journal of Cancer Research and Clinical Oncology|March 7, 2019
Reduced vs. standard dose native E. coli-asparaginase therapy in childhood acute lymphoblastic leukemia: long-term results of the randomized trial Moscow-Berlin 2002Alexander Karachunskiy, Gesche Tallen, Julia Roumiantseva, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|August 18, 2015
Strategies to improve the quality of survival for childhood brain tumour survivorsGesche Tallen, Anika Resch, Gabriele Calaminus, et al.
Pageof 2